• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Pediatrics

Evidence-based interventions for pediatric asthma successfully adapted for community health centers

byKate AndersonandCordelia Ross
May 9, 2017
in Pediatrics, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Interventions for pediatric asthma management found to be efficacious in prior randomized control trials (RCTs) showed similar rates of success when implemented at 3 diverse primary care centers.

2. The number of maximum symptom days (MSDs) reported by pediatric asthma patients at intervention sites were significantly lower than those reported at control sites.

Evidence Rating Level: 2 (Good)

Study Rundown: Adaptation of efficacious evidence-based interventions (EBI) from tightly controlled RCTs to real-world primary care centers often proves to be a challenge. In this study, researchers attempted to determine whether EBIs for pediatric asthma management found to be efficacious in previous RCTs* could be effectively implemented in community health centers (CHCs). Children aged 5 to 12 years with moderate to severe asthma were enrolled at 3 intervention sites and 3 capacity-matched control sites serving low resource, high risk populations in Arizona, Michigan, and Puerto Rico. Investigators worked with providers at intervention sites to create “minimum agreed upon interventions” based on components of the EBIs that seemed feasible for CHC staff. Using these modified interventions, results showed a significant reduction in number of symptom days in the previous 4 weeks in patients at the intervention versus control sites. These findings are consistent with results from the rigorous RCTs, despite geographically, demographically, and socioeconomic differences between CHC sites and patients compared with those studied in the RCTs. Furthermore, all 3 intervention sites in this study were able to successfully implement the agreed-upon interventions One limitation of this study is the lack of randomization of study participants to an intervention: control centers were identified based on similarity to previously selected intervention sites, and subjects were divided based on the center where they typically received care.  Nonetheless, the ability to successfully adapt EBIs into CHCs has implications for future policy and clinical care decisions that can improve outcomes for pediatric asthma patients.

Click to read the study, published today in Pediatrics

*Click to read the original NCICAS and ICAS randomized control trials

Relevant reading: Adapting and implementing an evidence-based asthma counseling intervention for resource-poor populations

RELATED REPORTS

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

Reliever-triggered inhaled glucocorticoid therapy in among Black and Latinx adults with asthma

Itepekimab provides beneficial effects for patients with moderate-to-severe asthma.

In-depth [non-randomized control trial]: Similar to the RCTs, participants were children aged 5 to 12 years with moderate to severe asthma; however, the study sites were primary care CHCs versus tertiary care centers where the original RCTs were conducted. A total of 590 children were enrolled from 3 intervention and 3 control sites in Arizona, Michigan and Puerto Rico, with 314 participants enrolled at intervention sites and 276 at control sites. On average, 78.5% of participants were Hispanic, with the family income of more than half the participants below $15000 per year. Patients from control sites had slightly higher asthma morbidity than those at intervention sites but were overall similar in terms of baseline severity and demographics. After working with CHC care providers to determine which EBI interventions could be feasibly implemented, all of the intervention sites averaged >4 asthma counseling visits, 96% of children received sensitivity counseling, and ~89% of homes were assessed for allergen exposures. MSDs were defined as the largest value among 3 asthma variables: number of days with wheezing, chest tightness or cough, number of nights asthma interfered with sleep, and number of days asthma interfered with daily activities.  Results show a significant decrease in MSDs reported over the last 4 weeks assessed at baseline, 6, and 12 months at intervention  compared to control sites (control, change of −2.28; intervention, change of −3.27; difference, −0.99; p<.001). These results were similar to those from the RCTs.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: asthma
Previous Post

Tofacitinib effective as induction and maintenance therapy for ulcerative colitis

Next Post

PCSK9 inhibitor significantly reduces the risk of cardiovascular events: The FOURIER trial

RelatedReports

Masks for personal protection for SARS-CoV-2 infection
Chronic Disease

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

April 5, 2022
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Chronic Disease

Reliever-triggered inhaled glucocorticoid therapy in among Black and Latinx adults with asthma

March 9, 2022
Combination salmeterol-fluticasone therapy noninferior to fluticasone monotherapy for asthma events: The VESTRI trial
Chronic Disease

Itepekimab provides beneficial effects for patients with moderate-to-severe asthma.

November 12, 2021
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Infectious Disease

Antenatal antibiotic exposure associated with increased risk of childhood asthma

November 2, 2021
Next Post
Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED

PCSK9 inhibitor significantly reduces the risk of cardiovascular events: The FOURIER trial

Use of plant-based therapies and menopausal symptoms

Antibiotics often overprescribed in elderly patients

USPSTF finds insufficient evidence for screening for iron deficiency anemia during pregnancy

Hepatitis C on the rise among reproductive-aged women

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.